Paula and Bobby
Parents of Lillie
Mucolipidosis Type IV
What is Mucolipidosis Type IV?
Mucolipidosis Type IV is a rare genetic condition first identified in 1974. Between then and 2010 only around 70 cases have been diagnosed.
70% of the cases of the syndrome are in individuals of Ashkenazi Jewish ancestry.
This lysosomal storage syndrome is metabolic and progressive. Characteristic features of the syndrome include delayed psychomotor development and visual impairment.
Ml Iv; Ml4 ML4 MLIV Sialolipidosis
What gene changes cause Mucolipidosis Type IV?
Mutations in the MCOLN1 gene are responsible for the syndrome. It is inherited in an autosomal recessive pattern.
Autosomal recessive inheritance means an affected individual receives one copy of a mutated gene from each of their parents, giving them two copies of a mutated gene. Parents, who carry only one copy of the gene mutation will not generally show any symptoms, but have a 25% chance of passing the copies of the gene mutations onto each of their children.
The syndrome is a lysosomal storage disease caused by a deficiency of arylsulfatase B (ASB) caused by mutations in the ARSB gene on chromosome 5.
What are the main symptoms of Mucolipidosis Type IV?
Typical Mucolipidosis Type IV is the severe form of the disorder and can cause serious symptoms. The atypical form of the disorder is much less severe and symptoms can vary widely between individuals.
Symptoms generally appear leading to a diagnosis in infancy, depending on their severity. These symptoms include poor muscular and mental coordination and reduced muscle tone.
Physical characteristics of the disorder include clouding of the cornea, retinal degeneration, crossed eyes, puffy eyelids, myopia and a hyper sensitivity to light.
Possible clinical traits/features:
Spastic tetraplegia, Progressive retinal degeneration, Strabismus, Infantile onset, Microcephaly, Genu recurvatum, Gait disturbance, Cognitive impairment, Incoordination, Hyperreflexia, Opacification of the corneal stroma, Abnormality of mucopolysaccharide metabolism, Abnormality of abdomen morphology, Cerebral dysmyelination, Cerebellar atrophy, Babinski sign, Abnormality of retinal pigmentation, Aplasia/Hypoplasia of the abdominal wall musculature, Absent speech, Palmoplantar keratoderma, Autosomal recessive inheritance, Nystagmus, Optic atrophy, Retinopathy, Photophobia, Everted lower lip vermilion, EEG abnormality, Decreased light- and dark-adapted electroretinogram amplitude, Developmental stagnation, Coarse facial features, Dystonia, Dysplastic corpus callosum, Intellectual disability, Muscular hypotonia, Abnormal electroretinogram, Abnormal nasal morphology, Ganglioside accumulation, Narrow forehead, Neurological speech impairment, Microdontia
How does someone get tested for Mucolipidosis Type IV?
The initial testing for Mucolipidosis Type IV can begin with facial analysis screening, through the FDNA Telehealth telegenetics platform, which can identify the key markers of the syndrome and outline the need for further testing. A consultation with a genetic counselor and then a geneticist will follow.
Based on this clinical consultation with a geneticist, the different options for genetic testing will be shared and consent will be sought for further testing.
Medical information on Mucolipidosis Type IV
Mucolipidosis IV is a neurodegenerative lysosomal storage disorder characterized by severe psychomotor delay and progressive visual impairment. Corneal clouding, retinal degeneration, increased blood gastrin levels and iron defficiency anemia are common manifestations. Mutations in the MCOLN1 gene cause this autosomal recessive disorder.
The main features of this condition are intellectual disability and clouding of the corneas, but the presentation can vary widely. Severe developmental delay, spasticity, hypotonia and the inability to walk independently are common and typically begin in early childhood. The MRI is thought to be characteristic (Frei et al., 1998). There is hypoplasia of the corpus callosum, with absent rostrum and a dysplastic or absent splenium, T1-weighted white matter changes and increased ferritin deposits in the thalami and basal ganglia. In the later stages of the disease, optic atrophy and a pigmentary retinopathy become apparent.
Cytoplasmic inclusions - in both single membrane-bound vesicles filled with granular material consistent with mucopolysaccharides and lamellar concentric bodies consistent with phospholipids - are found on EM of conjunctival and corneal biopsy material. Mild hepatosplenomegaly may be present. Facial dysmorphism is not a prominent feature, but puffy eyelids and a coarse face have been reported (Chitayat et al., 1991). The facial features may also coarsen with age.
Schiffmann et al., (1998) studied 15 patients and found an increased chance of iron deficiency. Gastroscopy in three patients showed that parietal cells contained large lysosomal inclusions. Constitutive achlorhydria was demonstrated.
About 50% of cases have been of Ashkenazi Jewish descent, and the carrier frequency in this population is 1 in 100 (Bargal et al., 2000).
In a follow-up study of 28 patients by Altarescu et al., (2002) all had achlorhydria with an elevated plasma gastrin level, and 12 had iron deficiency anemia. Mutations in the MCOLN1 gene were present in all.
Smith et al., (2002) reviewed the ophthalmic findings in 22 patients. All patients demonstrated some degree of corneal clouding, retinal vascular attenuation and optic nerve pallor. Extraocular motility disturbance (strabismus and/or nystagmus) was reported in 63%.
Note the four patients reported by Bindu et al., (2009) from India, who presented with spasticity. None had corneal or retinal problems, although one had optic atrophy. All had thinning of the corpus callosum.
Wakabayashi et al., (2011) argue Mucolipidosis Type IV is underrecognized due to its variable phenotypic presentation, and the disorder has been misdiagnosed as cerebral palsy.
Fisher et al., (2017) reported the longitudinal development of a child who participated in an augmentative and alternative communication intervention and showed improvement of expressive vocabulary.
Age of Onset:
The emergence of neurologic manifestations, such as severe psychomotor delay, is variable but usually starts in early childhood and typically in the first year of life. The onset of ophthalmologic symptoms, such as corneal clouding and retinal degeneration, also varies but is common during the first and second year of life.
Slaugenhaupt et al., (1999) mapped the gene to 19p13.2-13.3. Bargal et al., (2000), Sun et al., (2000) and Bassi et al., (2000) demonstrated mutations in a novel gene encoding a protein of 580 amino acids named mucolipin-1. There appeared to be one transmembrane helix and at least five transmembrane domains. It was speculated that this was a new ion channel protein.
From haplotype analysis, Bassi et al., (2000) identified two major founder mutations in the Ashkenazi Jewish population.
A method of rapid detection for the two common Ashkenazi Jewish mutations - (IVS3-1A->G and delEX1-EX7) - is reported by Wang et al., (2001).
Gilbert (2001) reviewed the possibility of carrier screening in Ashkenazi Jewish populations.
Edelmann et al., (2002) reported their experience in screening for carrier status in the American Ashkenazi Jewish population. The frequencies of the IVS3-2A-G and 511del6434 mutations were 0.54% and 0.25%, respectively, for a combined carrier frequency of 0.79% or 1 in 27 individuals (95% CI 0.40%-1.17%). The addition of both mutations causing this neurodegenerative disorder should be considered for parental carrier screening in this population.
Shiihara et al., (2016) described a male patient with mild clinical presentation; no corneal clouding was present. White matter volume reduction over time was observed; additional features were cerebellar atrophy, low signal intensities in the globus pallidi and thalami, and features suggestive of iron accumulation.
A male patient from a consanguineous family was reported by Gowda et al., (2017).
The two common Ashkenazi Jewish mutations are associated with a more severe presentation of the disease (Altarescu et al., 2002).
* This information is courtesy of the L M D.
If you find a mistake or would like to contribute additional information, please email us at: [email protected]
What is FDNA Telehealth?
FDNA Telehealth is a leading digital health company that provides faster access to accurate genetic analysis.
With a hospital technology recommended by leading geneticists, our unique platform connects patients with genetic experts to answer their most pressing questions and clarify any concerns they may have about their symptoms.
Benefits of FDNA Telehealth
Our platform is currently used by over 70% of geneticists and has been used to diagnose over 250,000 patients worldwide.
FDNA Telehealth provides facial analysis and screening in minutes, followed by fast access to genetic counselors and geneticists.
Ease of Use
Our seamless process begins with an initial online diagnosis by a genetic counselor and follows by consultations with geneticists and genetic testing.
Accuracy & Precision
Advanced artificial intelligence (AI) capabilities and technology with a 90% accuracy rate for a more accurate genetic analysis.
Faster access to genetic counselors, geneticists, genetic testing, and a diagnosis. As fast as within 24 hours if required. Save time and money.
Privacy & Security
We guarantee the utmost protection of all images and patient information. Your data is always safe, secure, and encrypted.